Skip to main content

emrosi

Generic: minocycline hydrochloride·Code: DFD-29

emrosi: developed by 1 company · 1 FDA decision.

emrosi evidence translation

What we can confirm

What it means

Source-backed records connect emrosi to DERM; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could emrosi → DERM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Papulopustular rosaceaInflammatory lesions of rosacea in adults

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
Journey Medical Corp (DERM)
Papulopustular rosacea
Phase 3
Journey Medical Corp (DERM)
Inflammatory lesions of rosacea in adults
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE EMROSI is indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults. Limitations of Use This formulation of minocycline has not been evaluated in the treatment or prevention of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, use EMROSI only as indicated. EMROSI is a tetracycline-class drug indicated to treat inflammatory lesions (papules and pustules) of rosac(DERM)FDA ↗
NDA219015Type 5 - New Formulation or New ManufacturerStandardOralCapsule, Extended Release

Frequently asked questions

Who is developing emrosi?

emrosi is being developed by Journey Medical Corp.

What is emrosi's latest FDA decision?

The most recent tracked FDA decision for emrosi is Approval for 1 INDICATIONS AND USAGE EMROSI is indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults. Limitations of Use This formulation of minocycline has not been evaluated in the treatment or prevention of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, use EMROSI only as indicated. EMROSI is a tetracycline-class drug indicated to treat inflammatory lesions (papules and pustules) of rosac, dated November 1, 2024.